Psilocybin with psychological support improves emotional face recognition in treatment-resistant depression
J. B. Stroud, Tom P. Freeman, Robert Leech, Chandni Hindocha, Will Lawn, D.j. Nutt, Hv Curran, R. L. Carhart-Harris
Psychopharmacology October 30, 2017 DOI: 10.1007/s00213-017-4754-y (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Observational cohort Placebo-controlled Peer reviewed |
|---|---|
| Sample size | 33 |
| Population | Patients with treatment-resistant depression and healthy controls |
| Intervention | Psilocybin with psychological support |
| Dose | two doses |
| Duration | 1 month |
| Topics | Depression Psilocybin |
| Citations | 102 |
| Key findings | Psilocybin with psychological support improved speed of emotion recognition in treatment-resistant depression, and this change correlated with reduced anhedonia. |
Abstract
Rationale: Depressed patients robustly exhibit affective biases in emotional processing which are altered by SSRIs and predict clinical outcome.
Objectives: The objective of this study is to investigate whether psilocybin, recently shown to rapidly improve mood in treatment-resistant depression (TRD), alters patients' emotional processing biases.
Methods: Seventeen patients with treatment-resistant depression completed a dynamic emotional face recognition task at baseline and 1 month later after two doses of psilocybin with psychological support. Sixteen controls completed the emotional recognition task over the same time frame but did not receive psilocybin.
Results: We found evidence for a group × time interaction on speed of emotion recognition (p = .035). At baseline, patients were slower at recognising facial emotions compared with controls (p < .001). After psilocybin, this difference was remediated (p = .208). Emotion recognition was faster at follow-up compared with baseline in patients (p = .004, d = .876) but not controls (p = .263, d = .302). In patients, this change was significantly correlated with a reduction in anhedonia over the same time period (r = .640, p = .010).
Conclusions: Psilocybin with psychological support appears to improve processing of emotional faces in treatment-resistant depression, and this correlates with reduced anhedonia. Placebo-controlled studies are warranted to follow up these preliminary findings.
Comparable studies
Other observational and cohort studies on psilocybin for depression, most cited first.
| Study | Year | Design | Participants |
|---|---|---|---|
| Psilocybin for treatment-resistant depression: fMRI-measured brain mechanisms. Patients with treatment-resistant depression | 2017 | Observational cohort | n = 19 |
| More Realistic Forecasting of Future Life Events After Psilocybin for Treatment-Resistant Depression Patients with treatment-resistant depression (TRD) | 2018 | Observational cohort | n = 15 |
| Natural speech algorithm applied to baseline interview data can predict which patients will respond to psilocybin for treatment-resistant depression. 17 patients with treatment-resistant depression and 18 untreated age-matched healthy... | 2018 | Observational cohort with machine learning classification | n = 35 |
| Brain dynamics predictive of response to psilocybin for treatment-resistant depression. Responders and non-responders to psilocybin therapy for depression | 2024 | Observational cohort | |
| Predicting the outcome of psilocybin treatment for depression from baseline fMRI functional connectivity. Patients with treatment-resistant depression or moderate-to-severe major depression | 2024 | Observational cohort | n = 38 |